Normustine
Nitrogen mustard used as a chemotherapy agent
 | |
| Clinical data | |
|---|---|
| Other names | Bis(2-chloroethyl)carbamic acid |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID |
|
| UNII |
|
| CompTox Dashboard (EPA) |
|
| Chemical and physical data | |
| Formula | C5H9Cl2NO2 |
| Molar mass | 186.03 g·mol−1 |
| 3D model (JSmol) |
|
| |
InChI
| |
Normustine, also known as bis(2-chloroethyl)carbamic acid, is a nitrogen mustard and alkylating antineoplastic agent (i.e., chemotherapy agent).[1][2][3] It is a metabolite of a number of antineoplastic agents that have been developed for the treatment of tumors, including estramustine phosphate, alestramustine, cytestrol acetate, and ICI-85966 (stilbostat), but only the former of which has actually been marketed.[1][2][3]
References
- ^ a b Brunton L, Chabner B, Knollman B (14 January 2011). Goodman and Gilman's The Pharmacological Basis of Therapeutics, Twelfth Edition. McGraw Hill Professional. p. 1709. ISBN 978-0-07-176939-6.
- ^ a b Fox BW, Fox M (6 December 2012). Antitumor Drug Resistance. Springer Science & Business Media. pp. 199–. ISBN 978-3-642-69490-5.
- ^ a b Decker M (5 April 2017). Design of Hybrid Molecules for Drug Development. Elsevier Science. pp. 201–. ISBN 978-0-08-101118-8.
- v
- t
- e
(M phase)
| Block microtubule assembly | |
|---|---|
| Block microtubule disassembly |
inhibitor
| DNA precursors/ antimetabolites (S phase) |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Topoisomerase inhibitors (S phase) |
| ||||||||
| Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
